Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
129.41
+2.13 (1.67%)
At close: Sep 11, 2026, 4:00 PM EDT
128.60
-0.81 (-0.63%)
Pre-market: Sep 14, 2026, 6:40 AM EDT
Insmed Market Cap
Insmed has a market cap or net worth of $28.26 billion as of September 11, 2026. Its market cap has decreased by -8.38% in one year.
Market Cap
28.26B
Enterprise Value
27.84B
1-Year Change
-8.38%
Ranking
Category
Stock Price
$129.41
ChartMarket Cap Chart
Since June 1, 2000, Insmed's market cap has increased from $409.10M to $28.26B, an increase of 6,808.03%. That is a compound annual growth rate of 17.48%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 28.26B | -23.86% |
| Dec 31, 2025 | 37.12B | 200.52% |
| Dec 31, 2024 | 12.35B | 178.59% |
| Dec 29, 2023 | 4.43B | 63.79% |
| Dec 30, 2022 | 2.71B | -16.06% |
| Dec 31, 2021 | 3.22B | -4.92% |
| Dec 31, 2020 | 3.39B | 58.95% |
| Dec 31, 2019 | 2.13B | 110.95% |
| Dec 31, 2018 | 1.01B | -57.65% |
| Dec 29, 2017 | 2.39B | 191.73% |
| Dec 30, 2016 | 818.60M | -27.02% |
| Dec 31, 2015 | 1.12B | 46.00% |
| Dec 31, 2014 | 768.30M | 15.55% |
| Dec 31, 2013 | 664.90M | 217.07% |
| Dec 31, 2012 | 209.70M | 177.01% |
| Dec 30, 2011 | 75.70M | -7.91% |
| Dec 31, 2010 | 82.20M | -18.05% |
| Dec 31, 2009 | 100.30M | 75.35% |
| Dec 31, 2008 | 57.20M | -43.08% |
| Dec 31, 2007 | 100.50M | 13.95% |
| Dec 29, 2006 | 88.20M | -17.72% |
| Dec 30, 2005 | 107.20M | 26.86% |
| Dec 31, 2004 | 84.50M | -25.88% |
| Dec 31, 2003 | 114.00M | 665.10% |
| Dec 31, 2002 | 14.90M | -88.15% |
View and export this data all the way back to 2000. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Revolution Medicines | 43.68B |
| BeOne Medicines AG | 39.40B |
| Royalty Pharma | 33.70B |
| Alnylam Pharmaceuticals | 33.28B |
| Roivant Sciences | 29.49B |
| Incyte | 24.62B |
| BioNTech SE | 24.30B |
| Genmab | 19.41B |